Scientific Advisory Board
OPKO’s Scientific Advisory Board is as follows:
Thomas Kodadek, Ph.D.
Dr. Kodadek is Professor and Vice Chairman of Chemistry at the Scripps Research Institute campus in Jupiter, FL. Previously, he held faculty positions at the University of Texas at Austin and the University of Texas Southwestern Medical Center in Dallas. Dr. Kodadek has made important contributions to understanding of how genes are rearranged and expressed. Recently, he has focused on the development of novel diagnostic and therapeutic tools for the treatment of immune diseases and cancers. This work was recognized in 2006 by a prestigious NIH Director’s Pioneer Award for “exceptionally creative research”. Dr. Kodadek received his B.S. in chemistry at the University of Miami and his Ph.D. in organic chemistry from Stanford University. He pursued post-doctoral studies in the laboratory of Professor Bruce Alberts at the University of California, San Francisco Medical School
Roger D. Kornberg, Ph.D.
Dr. Kornberg is the Winzer Professor in Medicine in the Department of Structural Biology at Stanford University, where he has taught since 1978. He has received many awards, including the Welch Prize (2001), the highest award in chemistry in the U.S., the Leopold Mayer Prize (2002), the highest award in biomedical sciences of the French Academy of Sciences, and the Nobel Prize in Chemistry (2006). Dr. Kornberg is a recipient of honorary degrees from universities in Europe and Israel, including the Hebrew University, where he is a visiting professor. Dr. Kornberg is a member of the National Academy of Sciences and an honorary member of other academies and professional societies in the U.S., Europe and Japan. Dr. Kornberg serves as a director of Protalix BioTherapeutics, Inc, Cocrystal Discovery, Inc. and OphthaliX Inc. He received a B.A. in chemistry from Harvard in 1967 and a Ph.D. in chemistry from Stanford in 1972.
Tahir Ahmed, M.D.
Dr. Ahmed is Director of Pulmonary Research at Mount Sinai Medical Center, Miami Beach, FL. He graduated from King Edward Medical College, Lahore, in 1973 and completed an Internal Medicine residency and fellowship in pulmonary diseases at Mount Sinai Medical Center. He joined the faculty of at both Mount Sinai Medical Center and University of Miami School of Medicine in 1979. He was an Assistant Associate Professor of Medicine at University of Miami from 1980 to 1992 and Professor of Medicine from 1992 to 2006. He also served as Chief of the Pulmonary Division at Mount Sinai Medical Center from 1996 to 2006. His research work has included pathophysiology of pulmonary circulation and bronchial asthma. He is the author of over 80 scientific publications. His current research is focused on studying the anti-inflammatory activity of heparin-derived oligosaccharides.
Richard A. Lerner, M.D.
Dr. Lerner has served as a director of OPKO since March 2007. Dr. Lerner served as President of The Scripps Research Institute, a private, non-profit biomedical research organization, from 1986 until 2011 and is currently serving as an institute professor. Dr. Lerner is a member of numerous scientific associations, including the National Academy of Sciences and the Royal Swedish Academy of Sciences. Dr. Lerner serves as director of Sequenom, Inc. (Nasal: SQNM), a life sciences company. He is also on the Board of Directors for Intra-Cellular Therapies, a privately held biotechnology company, and the board of Teva (NYSE:TEVA). He previously served as a director of Kraft Foods, Inc. and Xencor, a privately held biotechnology company, and on the Siemens’ Advisory Board for Molecular Medicine of Siemens AG.
As a result of Dr. Lerner’s long tenure as President of a major biomedical research organization, he provides valuable business, scientific, leadership, and management expertise that helps drive strategic direction and expansion at OPKO. His experience and training as a physician and a scientist enables him to bring valuable advice to the OPKO board, including a critical perspective on drug discovery and development and providing a fundamental understanding of a potential pathways contributing to disease.